|
S. aureusisolate
|
Cefoxitin MIC (μg/ml)
|
Cefoxitin AS*
|
Cefepime MIC (μg/ml)
|
Cefepime AS**
|
|---|
|
#1
|
3.0 ± 0.0
|
S
|
3.3 ± 0.3
|
S
|
|
#2
|
2.2 ± 0.4
|
S
|
1.7 ± 0.3
|
S
|
|
#6
|
3.0 ± 1.0
|
S
|
2.8 ± 0.7
|
S
|
|
#18
|
4.0 ± 1.0
|
I
|
2.0 ± 0.5
|
S
|
|
#19
|
6.0 ± 1.0
|
I
|
3.0 ± 0.6
|
S
|
|
#20
|
20.0 ± 2.3
|
R
|
7.0 ± 0.6
|
S
|
- *The Cefoxitin Antibiotic Susceptibility (AS) was determined using the CLSI Interpretive Criteria for cefoxitin as an oxacillin surrogate [41].
- ≤ 4 μg/ml - Susceptible (S), ≥ 8 μg/ml- Resistant (R), values in between Intermediate (I).
- **The Cefepime Antibiotic Susceptibility (AS) was determined using the CLSI Interpretive Criteria for cefepime [41].
- ≤ 8 μg/ml - Susceptible (S), 16 μg/ml - Intermediate (I), ≥ 32 μg/ml - Resistant (R)
- The results are presented as an average of three independent experiments as Average ± Std. Error. The CLSI recommended quality control for MIC for S. aureus, ATCC 29213 (#1) was included each time, and showed MIC within the expected range for cefoxitin (1–4 μg/ml) and cefepime (1–4 μg/ml) respectively.
